Merck & Co., Inc. (LON: MRK)

Market Cap	200.51B
Revenue (ttm)	47.13B
Net Income (ttm)	9.06B
Shares Out	n/a
EPS (ttm)	3.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,040
Open	50.50
Previous Close	50.50
Day's Range	50.00 - 50.70
52-Week Range	48.50 - 94.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv...

• Industry: Specialty Retail
• Sector: Consumer Discretionary
• Founded: 1891
• Employees: 72,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.

Financial numbers in USD